Peter Williams, PhD, Compound Development Team Leader, HIV Projects, Janssen Global Public Health, Belgium, discusses the LATTE-2 trial for HIV treatment.
Interview Transcript (slightly modified for readability)
“This is a trial in HIV-infected patients who were brought to < 50 copies/ml of virus in their plasma with an induction period with an oral treatment with cabotegravir and 2 nucleoside analogues for 20 weeks. Once they had reached that critical threshold of < 50 copies/ml in plasma, they were randomized to be given injectable of antiretrovirals either every 8 weeks or every 4 weeks. The two drugs that were given were rilpivirine long-acting injectable or cabotegravir (from ViiV healthcare). Rilpivirine is a nonnucleoside reverse transcriptase inhibitor, which is a Janssen product that is on the market in the oral form, but the long-acting injectable form is under development with us.
Once the randomization had happened, there was a group who were allowed to continue with their oral therapy, but about 115 patients were randomized to an every 8-week regimen [of the injectable regimen], and another 115 patients to every 4 weeks, and then about 55 patients remained on the oral therapy. We studied their viral load and their tolerability of the injections over the next almost 2 years—96 weeks in total.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512